Conclusion
renal cell carcinoma, non-clear cell renal cell carcinoma
RENAL CELL CARCINOMA
Tivozanib demonstrated activity and a favorable safety profile in patients with nccRCC. These data add to the body of evidence supporting the use of VEGFR-TKI in advanced nccRCC.Tivozanib is a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor that has demonstrated activity in renal cell carcinoma with clear cell component. This article reports on the efficacy of tivozanib in histologically diverse non-clear cell renal cell carcinoma.